CJC DAC 5mg USA peptides for sale

Introduction
CJC-1295 DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone (GHRH) analog developed to stimulate growth hormone (GH) production. Popular among bodybuilders due to its anabolic effects, it contributes to increasing muscle mass, burning fat and improving overall physical performance.
Anabolic Effects
1. Stimulation of Growth Hormone Release: CJC-1295 DAC stimulates the release of growth hormone in the pituitary gland. GH directly affects muscle growth and fat breakdown, thus having an anabolic effect.
2. Increase IGF-1 Level: Under the influence of growth hormone, the liver produces IGF-1 (insulin-like growth factor-1), which directly contributes to muscle growth and fat burning. Through its anabolic effect, IGF-1 enhances the proliferation and differentiation of muscle cells.
3. Fat burning: CJC-1295 DAC increases lipolysis, i.e. the breakdown of fat tissue, reducing body fat. This is especially beneficial for bodybuilders who want to achieve a low body fat percentage while maintaining muscle mass.
4. Regeneration and Healing: Increased GH and IGF-1 levels promote faster regeneration and healing of injuries. This is especially important for bodybuilders who follow intense training programs and often suffer minor injuries.
5. Longer Duration of Action: DAC (Drug Affinity Complex) technology allows CJC-1295 to have a longer duration of action, so fewer injections are needed. The effect of a single injection can last up to a week, which makes its use more convenient.
Use in Bodybuilders Circle
1. Dosage: Bodybuilders usually inject CJC-1295 DAC subcutaneously once or twice a week. The optimal dosage depends on the individual, but is usually between 1-2 milligrams per week.
2. Cyclic Use: The CJC-1295 DAC is often used cyclically, in 8-12 week cycles followed by 4-8 week rest periods. This helps prevent the body from getting used to it and maintains hormone efficiency.
3. Combination with Other Supplements: CJC-1295 DAC is often combined with other growth hormone releasing peptides (such as GHRP) or steroids for optimal anabolic effects. In addition, it can also be combined with nutritional supplements such as protein powders and BCAAs.
4. Diet and Exercise: To maximize the effects of CJC-1295 DAC, bodybuilders follow a strict diet and exercise regimen. A high-protein diet and adequate caloric intake are essential for muscle growth, while intense weight training and cardio work out to reduce body fat.
Side Effects and Risks
1. Water Retention and Edema: Some users may experience water retention and edema, especially in the extremities.
2. Appetite increase: CJC-1295 DAC can increase appetite, which can be beneficial for mass gain, but can be a problem for controlling body fat.
3. Hormonal Disturbances: Hormonal disturbances may occur with long-term use, so it is important to use cyclically and observe appropriate breaks.
4. Local Reactions: Redness, itching or pain may occur at the injection site.
Conclusion
CJC-1295 DAC can be an effective tool for bodybuilders to increase muscle mass, increase fat burning and promote regeneration. However, proper dosing, cyclical use, and monitoring of side effects are important. A medical consultation is definitely recommended before using CJC-1295 DAC to ensure safe and effective use.

 

Description

CJC 1295 has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC 1295 shown potential to increase growth hormone and IGF-I secretion and effects, but it has been able to do so in very large amounts. CJC 1295 Stimulates Growth Hormone Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to fat loss, and increased protein synthesis thereby promoting growth.

CJC 1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog.

One of the advantages of CJC 1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.

CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. A potential drawback when using a weekly protocol can be attributed to ineffective GHRH stimulation when the body is due for a GH spike (usually 1:00am). This is referred to as a GH-bleed and the overall result is inferior to using CJC 1295-NON-DAC daily for 5 days out of 7. Therefore using CJC 1295-NON-DAC daily (between 6-8pm) provides a more effective GH spike at 1:00am.

Various experiments have been conducted to test the effectiveness of CJC 1295-DAC in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection. Mean half-life was shown to be 5.8-8.1 days, also after multiple doses mean IGF-1 levels remained above baseline for up to 28 days. No serious adverse reactions were reported in any group.

Another benefit of CJC 1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS decreases significantly in older adults and also with people who tend to exercise later in the evening. Clinical studies have shown that a once-daily administration of CJC 1295 normalizes the GHRH response and can induce significantly deeper sleep.

Clinical Research

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC 1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults – Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, and Lawrence A. Frohman.

WinPharm Associates (S.L.T., A.N.), Alamo, California 94507; ConjuChem, Inc. (B.L., C.G., J.-P.C.), Montre´al, Que´be´c, Canada; and Section of Endocrinology, Department of Medicine, University of Illinois (L.A.F.), Chicago, Illinois 60612

Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.

Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC 1295, a long-acting GHRH analog.

Design: The study design was two randomized, placebo-controlled, double blind, ascending dose trials with durations of 28 and 49 d.

Setting: The study was performed at two investigational sites.

Participants: Healthy subjects, ages 21–61 yr, were studied.

Interventions: CJC 1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.

Main Outcome Measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC 1295.

Results: After a single injection of CJC 1295, there were dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC 1295 was 5.8–8.1 d. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.

Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.

Write a review

Your Name:


Your Review: Note: HTML is not translated!

Rating: Bad           Good

Enter the code in the box below: